mefloquine hydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
mefloquine hydrochloride: clinical details
Prescribing considerations
- Base prophylaxis on destination-specific malaria risk and resistance patterns plus the traveller's medical, psychiatric and medication history.
- Discuss the distinctive neuropsychiatric risk and provide clear instructions to stop prophylactic mefloquine and obtain immediate review if mental-state changes occur.
- Assess cardiac conduction disease, hepatic or renal impairment, neurological symptoms, visual problems and activities requiring balance or fine coordination.
- The presence of lactose may matter in rare hereditary disorders of galactose metabolism.
Contraindications and cautions
- Hypersensitivity to mefloquine, related compounds such as quinine or quinidine, or formulation excipients.
- For chemoprophylaxis: current or previous depression, anxiety disorder, psychosis, schizophrenia, suicidal behaviour, other psychiatric disorder or convulsions of any origin.
- Halofantrine use during mefloquine exposure or its prolonged post-treatment elimination period.
- History of blackwater fever.
- Severe hepatic impairment.
Monitoring
- Actively review new psychiatric, neurological, vestibular, visual, cardiac, respiratory or hypersensitivity symptoms.
- Consider antiseizure medicine concentrations where concurrent treatment is unavoidable.
- For prolonged use, undertake periodic liver-function and ophthalmic assessment.
- Refer visual disturbance for medical assessment; stop and assess new peripheral neuropathy symptoms.
Clinical pharmacology
Mefloquine is highly protein-bound, extensively metabolised in the liver mainly through CYP3A4 and has a long elimination half-life. Food increases absorption. It acts against susceptible asexual intraerythrocytic Plasmodium forms but not dormant hypnozoites.
Formulation and product differences
- The selected products are white to off-white, cross-scored oral tablets supplied in moisture-protective foil packaging.
- The formulation contains lactose monohydrate.
mefloquine hydrochloride preparations and strengths
Tablet
Route: Oral
Strengths: 250 mg
mefloquine hydrochloride interactions
Review all prescription, non-prescription and travel medicines before mefloquine is supplied.
Halofantrine
Must not be combined with mefloquine or used during its prolonged elimination period because potentially fatal QT prolongation may occur.
Quinine, quinidine or chloroquine
Concurrent or closely sequenced use may increase cardiac conduction abnormalities or seizure risk and requires specialist management.
QT-prolonging medicines
Antiarrhythmics, beta-blockers, calcium-channel blockers, some antihistamines, tricyclic antidepressants and phenothiazines may add to cardiac conduction risk.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.